Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Latest news very good

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Feb 15, 2024 2:14pm

206 Views

Post# 35882399

RE:Latest news very good

A buyout by Roche could happen anytime.

It needs to happen very soon otherwise ONC is facing a capital raise that will decimate existing shareholders.

No one "invests" by buying shares in ONC at this time. It is a pure speculative gamble with a timeframe of less than two months.

Roche buyout... you win at least 10x

Dilutive financing ... you lose half your money, likely never to see it recover.

Given that MC is CEO, I place the odds at less than 5% in favour of buyout.

With any other CEO, ONC might be worth a small gamble at this moment.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec